Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study

@article{LoRusso2013IcrucumabAF,
  title={Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study},
  author={Patricia M. LoRusso and Smitha S. Krishnamurthi and Hagop Youssoufian and Nancy Hall and Floyd E. Fox and Aruna Dontabhaktuni and Dmitri O. Grebennik and Scot C. Remick},
  journal={Investigational New Drugs},
  year={2013},
  volume={32},
  pages={303-311}
}
SummaryBackground IMC-18F1 (icrucumab), a human monoclonal antibody against vascular endothelial growth factor receptor-1 (VEGFR-1), potently inhibits ligand-dependent phosphorylation of VEGFR-1 and downstream signaling, making icrucumab an attractive candidate for antitumor activity. Objectives The primary objective was to determine the safety profile and maximum tolerated dose of icrucumab in patients with advanced solid tumors that were previously unresponsive to standard therapy or for… 
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
TLDR
Combining RAM or ICR with CAP did not improve PFS in the targeted study population, and strong preclinical and clinical evidence suggests key roles for VEGF and angiogenesis in breast cancer growth, invasion, and metastasis.
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.
  • D. Petrylak, S. Tagawa, K. Chi
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
TLDR
The addition of ramucirumab to docetaxel met the prespecified efficacy end point for prolonging PFS in patients with locally advanced or metastatic urothelial carcinoma receiving second-line treatment and warrants further investigation in the phase III setting.
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
  • M. Moore, S. Gill, E. Strevel
  • Biology, Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2016
TLDR
Combining ramucirumab or icrucumab with mFOLFOX-6 did not achieve the predetermined improvement in PFS and the most frequent adverse events reported were fatigue, nausea, and peripheral sensory neuropathy.
Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies
TLDR
The efficacy and tolerability of approved and investigational antiangiogenic agents for the treatment of mCRC are summarized and potential markers of response to antiangIogenic agents are discussed, including how these markers can improve clinical trial design.
A critical review on ramucirumab in the treatment of advanced urothelial cancer.
TLDR
Improvements in ability to predict responses and resistance are key for maximizing its efficacy and selecting the most appropriate combinations with other active agents in advanced urothelial cancer.
VEGFR-1 Overexpression Identifies a Small Subgroup of Aggressive Prostate Cancers in Patients Treated by Prostatectomy
TLDR
High level VEGfr-1 expression is infrequent in prostate cancer, but identifies a subgroup of aggressive cancers, which may be candidates for anti-VEGFR-1 targeted therapy.
Tumor angiogenesis revisited: Regulators and clinical implications
TLDR
Recently identified angiogenesis mediators and pathways, new concepts that have emerged over the past 10 years, tumor resistance and toxicity associated with the use of currently available antiangiogenic treatment and potentially new targets and/or approaches for malignant and nonmalignant neovascular diseases are discussed.
Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy
TLDR
Several molecular agents for intervening in the activity of different signalling pathways are being explored in TNBC, but none has so far proved effective in clinical trials and the disease continues to pose a defining challenge for clinical management as well as innovative cancer research.
...
...

References

SHOWING 1-10 OF 28 REFERENCES
Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer
TLDR
IMC-18F1 anti-VEGFR-1 has potential to provide clinical benefit to cancer patients and was evaluated in human breast cancer xenograft models and enhanced the antitumor efficacy of cytotoxic agents commonly used to treat breast cancer.
Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.
TLDR
It is demonstrated here that human lymphoma cells secrete vascular endothelial growth factor (VEGF) and express VEGF receptor 1 (VEGFR-1) and VEGFR-2 and that combining DC101 with therapeutic agents consistently improved tumor responses over those of single-agent therapy.
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.
TLDR
The development of rash with tyrosine kinase inhibitors or monoclonal antibodies targeting the epidermal growth factor receptor is associated with superior outcomes in lung, head and neck, colorectal, and pancreatic cancer studies and may be a marker of effective target inhibition.
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
TLDR
2C3 has potent antitumor activity, inhibiting the growth of newly injected and established human tumor xenografts in mice and highlighting the dominant role of VEGFR2 in mediating VEGF-induced vascular permeability increase and tumor angiogenesis.
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
TLDR
This Review will discuss the rationale for using antiangiogenic compounds and will focus on large molecules, such as antibodies, that target the VEGF system, and clinical data on bevacizumab is discussed in detail.
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
TLDR
Despite this milestone, anti-angiogenic therapy still faces a number of clinical hurdles, such as improving efficacy, avoiding escape and resistance, and minimizing toxicity.
Vascular endothelial growth factor receptor‐1 in human cancer
TLDR
The preliminary results of phase 1 investigations have indicated a favorable safety profile for IMC‐18F1 at doses that confer antibody concentrations that are associated with relevant antitumor activity in preclinical models.
Targeting the VEGF signaling pathway in cancer therapy
TLDR
This review discusses recent data regarding the molecular mechanisms of VEGF signaling in cancer development, the response of various types of human cancer to anti-VEGF treatment, reasons for a failure of therapy and possible biomarkers for the prediction of therapeutic response.
Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
TLDR
The possibility that concurrent targeting of VEGF-A and PlGF might improve the clinical effectiveness of antiangiogenic therapy in the treatment of malignant and nonmalignant diseases is examined.
Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer.
TLDR
The results indicate that the VEGF gene is frequently overexpressed in TCC of the urinary bladder, especially in muscle invasive tumors, and that a paracrine system including VegF and flt-1 exists between the TCC cells and the adjacent endothelial cells so as to regulate the angiogenesis in this tumor.
...
...